Medical Condition News

RSS

Pfeiffer Treatment Center opens new Alzheimer’s care center in Illinois

Pfeiffer Treatment Center proudly announces that it has opened the Pfeiffer Center for Alzheimer’s care in Illinois.

1 Oct 2009

Bristol-Myers announces availability of ERBITUX for metastatic colorectal cancer treatment

Bristol-Myers Squibb Canada is pleased to announce that the Ontario government has made ERBITUX(TM) (cetuximab) available to patients suffering from metastatic colorectal cancer. This decision makes Ontario the second province, after British Columbia, to introduce funding for this important treatment option and represents encouraging news for those patients who rely on provincial drug coverage and stopped responding to standard treatments for metastatic colon cancer.

1 Oct 2009

Patients with serious mental illness need to be treated for physical and mental health

New research backs up the demand to integrate psychiatric care with primary care services for people with serious mental disorders in Ontario, according to a study published today. "Patients need their care providers to close that gap," says lead author Dr. Russell Callaghan of the Centre for Addiction and Mental Health (CAMH) in Toronto.

1 Oct 2009

New medical breakthrough by Bioheart for treatment of patients with heart disorders

Bioheart, Inc. offers yet another medical breakthrough with the next-level stem cell treatment for cardiac patients. The stem cells aid in limiting damage due to a cardiac event and promote angiogenesis or formation of new blood vessels.

1 Oct 2009

Streptococcal infection does not cause OCD or Tourette syndrome, says study

New research shows that streptococcal infection does not appear to cause or trigger Tourette syndrome or obsessive-compulsive disorder (OCD). The research is published in the September 30, 2009, online issue of Neurology®, the medical journal of the American Academy of Neurology.

1 Oct 2009

NCI and NHGRI collaborate to characterize genetic and genomic changes that occur in cancers

The University of North Carolina at Chapel Hill is one of twelve centers announced today by President Obama as part of an unprecedented large-scale, collaborative effort by the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI) to systematically characterize the genomic changes that occur in cancer.

1 Oct 2009

New drug combination releives neuropathic pain and improves sleep

People who suffer from debilitating neuropathic pain may get more relief and sleep better by combining two commonly-prescribed drugs.

1 Oct 2009

New Pathways to Memory Program to improve cognitive function for patients with dementia

Based on the ground-breaking program released in 2005, Homewatch CareGivers (www.HomewatchCareGivers.com), the largest, most experienced international provider of full-service home care, announced the release of its newly expanded Pathways to Memory™ Program, a set of therapeutic activities delivered in a nurturing, failure-free environment that stimulates and enhances cognitive function for patients with early to mid stage dementia, Alzheimer’s disease, and other memory loss conditions.

1 Oct 2009

Peanuts can help control obesity in children

A landmark study published in Obesity shows that, 80% of high-risk adolescents decreased or maintained weight, while almost 65% of the control group gained at one year.

1 Oct 2009

Alcoholism affects sleep even after long periods of abstinence for both men and women, says study

A study in the Oct.1 issue of the journal Sleep shows that long-term alcoholism affects sleep even after long periods of abstinence, and the pattern of this effect is similar in both men and women.

1 Oct 2009

Resverlogix RVX-208 exceeds expectations in Phase 1b/2a clinical trial

Resverlogix Corp. announced today that results from the Company's Phase 1b/2a clinical trial have met and exceeded expectations by successfully concluding the drug, RVX-208, is safe and tolerable. Most importantly RVX-208 has met its primary endpoint to increase the production of plasma ApoA-I, the key cardioprotective protein in high-density lipoprotein (HDL), often referred to as "good" cholesterol.

1 Oct 2009

Antidepressant amitriptyline works just as well as placebo for children with gastrointestinal disorders

When used "off-label," the antidepressant amitriptyline works just as well as placebo in treating pain-predominant gastrointestinal disorders in children, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association (AGA) Institute. To view this article's video abstract, go to the AGA's YouTube Channel at www.youtube.com/AmerGastroAssn.

1 Oct 2009

EMD Serono submits NDA for Cladribine Tablets in the U.S.

EMD Serono, Inc. an affiliate of Merck KGaA, Darmstadt, Germany, announced today the submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for Cladribine Tablets, EMD Serono's proprietary investigational oral formulation of cladribine, as a therapy for reducing relapses in people with relapsing forms of multiple sclerosis (MS).

1 Oct 2009

Ardea's to present its hyperuricemia canditate study results at the ACR/ARHP Scientific Meeting

Ardea Biosciences, Inc. announced that it will present results from a Phase 2a, proof-of-concept study of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout, at the 2009 American College of Rheumatology (ACR) / Association of Rheumatology Health Professionals (ARHP) Annual Scientific Meeting in Philadelphia, Pennsylvania.

1 Oct 2009

Cost-effective screening test for coronary artery disease

A simple, non-invasive test appears to be an effective screening tool for identifying patients with silent heart disease who are at risk for a heart attack or sudden death.

1 Oct 2009

Participants seek depression treatment post initial screening, according to NDSD study

Screening for Mental Health, Inc., the leading nonprofit provider of online and in-person mental health screening programs, today released results from a follow-up study of participants in the 2008 National Depression Screening Day® (NDSD) online program.

1 Oct 2009

PSA test vital for assessing prostate cancer

When it comes to the prostate cancer, the disease known as the "silent killer" because it often exhibits no symptoms, to be forewarned is to be forearmed. It is the second leading cancer killer in men, just behind lung cancer. Every year, more than 218,000 men are diagnosed with prostate cancer in the United States, claiming about 28,000 lives.

1 Oct 2009

Can-Fite BioPharma commences preparatory work for a Phase III trial with CF101 to treat Psoriasis

Can-Fite BioPharma, a biotechnology company traded on the Tel Aviv Stock Exchange, an Israeli Biopharmaceutical company, announced today the initiation of preparatory work for a Phase III trial with CF101 in Psoriasis. This is based on the successful conclusion of a Phase II dose-response clinical study with CF101 to treat patients with moderate to severe Psoriasis; the study successfully met its primary objective of efficacy and safety

1 Oct 2009

Study reveals how kidney repair processes are controlled

A study by Monash University researchers has shed new light on the microscopic antennas in the kidney that are involved in the organ's repair process.

1 Oct 2009

Scientists report new development for diagnosing malignant melanoma

Scientists in Australia are reporting development and testing in laboratory animals of a potential new material for diagnosing malignant melanoma, the most serious form of skin cancer. Their study is scheduled for the September 10 issue of the ACS' Journal of the Medicinal Chemistry, a bi-weekly publication.

1 Oct 2009

Medical Condition News

Pfeiffer Treatment Center opens new Alzheimer’s care center in Illinois

Bristol-Myers announces availability of ERBITUX for metastatic colorectal cancer treatment

Patients with serious mental illness need to be treated for physical and mental health

New medical breakthrough by Bioheart for treatment of patients with heart disorders

Streptococcal infection does not cause OCD or Tourette syndrome, says study

NCI and NHGRI collaborate to characterize genetic and genomic changes that occur in cancers

New drug combination releives neuropathic pain and improves sleep

New Pathways to Memory Program to improve cognitive function for patients with dementia

Peanuts can help control obesity in children

Alcoholism affects sleep even after long periods of abstinence for both men and women, says study

Resverlogix RVX-208 exceeds expectations in Phase 1b/2a clinical trial

Antidepressant amitriptyline works just as well as placebo for children with gastrointestinal disorders

EMD Serono submits NDA for Cladribine Tablets in the U.S.

Ardea's to present its hyperuricemia canditate study results at the ACR/ARHP Scientific Meeting

Cost-effective screening test for coronary artery disease

Participants seek depression treatment post initial screening, according to NDSD study

PSA test vital for assessing prostate cancer

Can-Fite BioPharma commences preparatory work for a Phase III trial with CF101 to treat Psoriasis

Study reveals how kidney repair processes are controlled

Scientists report new development for diagnosing malignant melanoma

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News